{"version":"1.0","provider_name":"NOBEL Pharma Schweiz AG","provider_url":"https:\/\/nobelpharma.ch\/fr\/","title":"NOBEL Pharma Schweiz AG | NOUVEAU SUR LE MARCH\u00c9 SUISSE : SOLIF\u00c9NACINE NOBEL","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"WaxSA1N4Np\"><a href=\"https:\/\/nobelpharma.ch\/fr\/2021\/01\/nouveau-sur-le-marche-suisse-solifenacin-nobel\/\">NOUVEAU SUR LE MARCH\u00c9 SUISSE : SOLIF\u00c9NACINE NOBEL<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/nobelpharma.ch\/fr\/2021\/01\/nouveau-sur-le-marche-suisse-solifenacin-nobel\/embed\/#?secret=WaxSA1N4Np\" width=\"600\" height=\"338\" title=\"\u00ab\u00a0NOUVEAU SUR LE MARCH\u00c9 SUISSE : SOLIF\u00c9NACINE NOBEL\u00a0\u00bb &#8212; NOBEL Pharma Schweiz AG\" data-secret=\"WaxSA1N4Np\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/nobelpharma.ch\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","thumbnail_url":"https:\/\/nobelpharma.ch\/wp-content\/uploads\/2022\/01\/urogential.jpg","thumbnail_width":1000,"thumbnail_height":288,"description":"Au moment de l\u2019expiration du brevet de Vesicare, NOBEL \u00e9largit sa gamme de produits urologiques avec Solif\u00e9nacine NOBEL. Le principe actif appartient au groupe des parasympatholytiques, qui sont utilis\u00e9s pour le traitement de l\u2019instabilit\u00e9 (hyperactivit\u00e9) v\u00e9sicale. Le Solifenacin est un inhibiteur comp\u00e9titif et s\u00e9lectif du r\u00e9cepteur muscarinique de sous-type M3, qui joue un r\u00f4le important [&hellip;]"}